Accuray (ARAY)
(Delayed Data from NSDQ)
$1.73 USD
-0.17 (-8.95%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.73 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
ARAY 1.73 -0.17(-8.95%)
Will ARAY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARAY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARAY
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
ARAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks
Other News for ARAY
Lake Street Keeps Their Buy Rating on Accuray (ARAY)
Archon Capital Management LLC Adjusts Stake in Accuray Inc
Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact? System and VitalHold? Solution
Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
Accuray Announces CEO Medical Leave and Interim Successor